Lorcaserin - Eisai Inc

Drug Profile

Lorcaserin - Eisai Inc

Alternative Names: APD-356; Belviq; Belviq XR; Lorcaserin controlled-release; Lorcaserin extended-release; Lorcaserin hydrochloride; Venespri

Latest Information Update: 30 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Arena Pharmaceuticals
  • Developer Arena Pharmaceuticals; CY Biotech; Eisai Inc; Ildong Pharmaceutical
  • Class Benzazepines; Obesity therapies; Small molecules
  • Mechanism of Action Serotonin 2C receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Obesity
  • Discontinued Smoking withdrawal

Most Recent Events

  • 27 Aug 2018 Long-term efficacy and adverse events data from the phase III/IV CAMELLIA-TIMI 61 trial in Obesity released by Eisai
  • 27 Aug 2018 Eisai completes the phase III/IV CAMELLIA-TIMI 61 trial in Obesity in USA, Australia, Brazil, Canada, Chile, Czech Republic, Germany, Ireland, Mexico, the Netherlands, New Zealand, Poland, and United Kingdom
  • 23 Aug 2018 Eisai plans a phase I trial in healthy volunteers in USA , (NCT03627936)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top